公开(公告)号：US11793771B2

公开(公告)日：2023-10-24

申请号：US17838400

申请日：2022-06-13

Applicant: CHEMOCENTRYX, INC.

Inventor： Christopher Lange ,  Viengkham Malathong ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/085 ,  C07D211/40 ,  A61P35/00 ,  C07C215/12 ,  C07F5/02 ,  C07D401/14 ,  C07D213/30 ,  C07D405/12 ,  C07C229/22 ,  C07D319/18 ,  C07D417/12 ,  A61K45/06 ,  C07C235/42 ,  C07C235/20 ,  C07D239/42 ,  C07C255/54 ,  C07D213/61 ,  C07D413/12 ,  C07D205/04 ,  A61P31/00 ,  C07D237/08 ,  C07D401/12 ,  C07D213/85 ,  C07D239/30 ,  C07D405/14 ,  C07D401/04 ,  C07D409/12 ,  C07D213/80 ,  A61P29/00 ,  C07C317/22 ,  C07F9/58 ,  A61K31/015 ,  A61K31/03 ,  A61K31/277 ,  A61K38/00 ,  C07C43/168 ,  A61K31/36 ,  A61K31/44 ,  A61K31/505 ,  A61K47/34

CPC classification number: A61K31/085 ,  A61K31/015 ,  A61K31/03 ,  A61K31/277 ,  A61K38/00 ,  A61K45/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  C07C43/168 ,  C07C215/12 ,  C07C229/22 ,  C07C235/20 ,  C07C235/42 ,  C07C255/54 ,  C07C317/22 ,  C07D205/04 ,  C07D211/40 ,  C07D213/30 ,  C07D213/61 ,  C07D213/80 ,  C07D213/85 ,  C07D237/08 ,  C07D239/30 ,  C07D239/42 ,  C07D319/18 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07F5/025 ,  C07F9/58 ,  A61K31/36 ,  A61K31/44 ,  A61K31/505 ,  A61K47/34 ,  C07C2601/02 ,  C07C2602/08 ,  Y02A50/30

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):






including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US11603356B2

公开(公告)日：2023-03-14

申请号：US17091001

申请日：2020-11-06

Applicant: CHEMOCENTRYX, INC.

Inventor： Kwok Yau ,  Kenken Luong ,  Rajinder Singh ,  Yibin Zeng ,  Penglie Zhang ,  Manmohan Reddy Leleti ,  Rebecca M. Lui

IPC: C07D211/60 ,  A61K9/00

Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.

公开(公告)号：US11485737B2

公开(公告)日：2022-11-01

申请号：US16939667

申请日：2020-07-27

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher W. Lange ,  Rebecca M. Lui ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Sreenivas Punna ,  Rajinder Singh ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D487/04 ,  A61K9/00 ,  A61K31/4162 ,  A61K45/06 ,  A61P35/00 ,  A61P19/02 ,  A61P11/00 ,  A61P25/28 ,  A61P37/06 ,  A61P7/00 ,  A61K9/10 ,  A61K9/08 ,  A61P37/00

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

公开(公告)号：US11446289B2

公开(公告)日：2022-09-20

申请号：US16553339

申请日：2019-08-28

Applicant: CHEMOCENTRYX, INC.

Inventor： Shijie Li ,  Venkat Reddy Mali ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/4545 ,  A61K39/395 ,  A61P35/00 ,  A61K31/357 ,  A61K31/165

Abstract: The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

公开(公告)号：US11426364B2

公开(公告)日：2022-08-30

申请号：US16751019

申请日：2020-01-23

Applicant: CHEMOCENTRYX, INC.

Inventor： Christopher Lange ,  Viengkham Malathong ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61P31/00 ,  A61K31/085 ,  C07D211/40 ,  A61P35/00 ,  C07C215/12 ,  C07F5/02 ,  C07D401/14 ,  C07D213/30 ,  C07D405/12 ,  C07C229/22 ,  C07D319/18 ,  C07D417/12 ,  A61K45/06 ,  C07C235/42 ,  C07C235/20 ,  C07D239/42 ,  C07C255/54 ,  C07D213/61 ,  C07D413/12 ,  C07D205/04 ,  C07D237/08 ,  C07D401/12 ,  C07D213/85 ,  C07D239/30 ,  C07D405/14 ,  C07D401/04 ,  C07D409/12 ,  C07D213/80 ,  A61P29/00 ,  C07C317/22 ,  C07F9/58 ,  A61K31/015 ,  A61K31/03 ,  A61K31/277 ,  A61K38/00 ,  C07C43/168 ,  A61K31/36 ,  A61K31/44 ,  A61K31/505 ,  A61K47/34

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US11154556B2

公开(公告)日：2021-10-26

申请号：US16241391

申请日：2019-01-07

Applicant: CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： James J. Campbell ,  Rajinder Singh ,  Samuel Hwang ,  Xuesong Wu

IPC: A61K31/536 ,  A61P35/00 ,  A61K45/06 ,  A61K31/4433 ,  A61K31/453

Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I:

公开(公告)号：US10919852B2

公开(公告)日：2021-02-16

申请号：US16047545

申请日：2018-07-27

Applicant: CHEMOCENTRYX, INC.

Inventor： Christopher Lange ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Yu Wang ,  Ju Yang ,  Penglie Zhang

IPC: C07D401/12 ,  C07D401/10 ,  A61P37/02 ,  C07D207/12 ,  A61K45/06 ,  C07D207/267 ,  C07D211/44 ,  C07D403/12 ,  C07D211/38 ,  C07D451/06 ,  C07D205/12 ,  C07F5/02 ,  C07D405/14 ,  C07D401/14 ,  C07D471/10 ,  C07D211/76 ,  C07D205/04 ,  C07D213/85 ,  C07D295/088 ,  C07D487/10 ,  C07D405/12 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/40 ,  C07D211/46

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US20180140587A1

公开(公告)日：2018-05-24

申请号：US15821490

申请日：2017-11-22

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61P13/12 ,  A61K31/519 ,  A61K31/4184 ,  A61K31/403 ,  A61K31/4422 ,  A61K31/4178 ,  A61K39/395 ,  A61K31/7034 ,  A61K31/28 ,  A61K31/4418 ,  A61K31/137 ,  A61K31/44 ,  A61K31/426 ,  A61K35/545

CPC classification number: A61K31/444 ,  A61K31/137 ,  A61K31/28 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/7034 ,  A61K35/545 ,  A61K39/3955 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US11883391B2

公开(公告)日：2024-01-30

申请号：US17219172

申请日：2021-03-31

Applicant: ChemoCentryx, Inc.

Inventor： James Campbell ,  Israel Charo ,  Thomas Schall ,  Rajinder Singh ,  Yibin Zeng ,  Penglie Zhang

IPC: A61K31/4709 ,  C07K16/24 ,  A61P1/00 ,  A61K31/4402 ,  C07K16/28

CPC classification number: A61K31/4709 ,  A61K31/4402 ,  A61P1/00 ,  C07K16/244 ,  C07K16/2866

Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

公开(公告)号：US11608336B2

公开(公告)日：2023-03-21

申请号：US16982817

申请日：2019-04-01

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Rebecca M. Lui ,  Rajinder Singh ,  Venkat Reddy Mali ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D471/04 ,  C07D487/04 ,  A61P19/02 ,  A61P27/02 ,  A61P9/10 ,  A61P37/06 ,  A61P13/12 ,  A61P11/00 ,  A61P9/14 ,  A61P35/00 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4162 ,  A61K31/506 ,  A61K31/675 ,  C07F9/6561

Abstract: The present disclosure provides, inter alia, Compounds of Formulae IA, IB, IC, IIA, IIB and IIC or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.